GlassScriptPhysician profile
Kevin R Ferguson
NPI 1164530036
$43,682.09
in general payments reported to CMS, 2019-2025
33 companies · $3,941 in 2025
The $3,941 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,686 · 2020: $6,894 · 2021: $2,510 · 2022: $5,416 · 2023: $18K · 2024: $3,469 · 2025: $3,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $10K · Travel and Lodging: $982 · Consulting Fee: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,260.00 |
| Food and Beverage | $10,432.04 |
| Travel and Lodging | $981.61 |
| Consulting Fee | $502.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17,903.56 | 2022-2025 | Quviviq, Quviviq |
| Allergan, INC. | $7,166.76 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $2,885.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $2,467.71 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,326.23 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,282.72 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,122.26 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Corium, LLC | $1,013.99 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $947.73 | 2023-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $892.70 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $870.66 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $759.74 | 2019-2025 | Fanapt |
| Abbvie INC. | $759.29 | 2021-2025 | |
| Lundbeck LLC | $710.74 | 2019-2025 | Rexulti, Brintellix |
| Sunovion Pharmaceuticals INC. | $697.73 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $662.56 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Eisai INC. | $338.75 | 2020-2022 | |
| Almatica Pharma LLC | $314.39 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $299.30 | 2019-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $244.49 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $214.40 | 2019-2023 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $166.95 | 2019-2022 | |
| Tris Pharma INC | $119.11 | 2022-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $109.91 | 2025 | Jornay Pm |
| Shire North American Group INC | $83.92 | 2019 | |
| Bausch Health US, LLC | $79.22 | 2019-2022 | |
| Adlon Therapeutics L.P. | $59.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.55 | 2020-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $56.25 | 2021 | |
| Noven Therapeutics, LLC | $23.76 | 2024 | Xelstrym, Secuado |
| Rhodes Pharmaceuticals L.P. | $16.37 | 2019 | |
| Alfasigma USA, INC. | $15.70 | 2022 | |
| Neuronetics, INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.